Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
38.09 (1y: -1%)
Market Cap 2.57 B P/E(ttm)
Enterprise Value 2.47 B P/B 10.40
CPHD- NAS (USA)
Cepheid
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$38.09
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 51.274
CPHD's Cash to Debt is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.36 vs. CPHD: 51.274 )
CPHD' s 10-Year Cash to Debt Range
Min: 0.88   Max: 11006.5
Current: 51.27
0.88
11006.5
Equity to Asset 0.576
CPHD's Equity to Asset is ranked lower than
1098900% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CPHD: 0.576 )
CPHD' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.9
Current: 0.58
0.25
0.9
F-Score: 2
Z-Score: 17.2
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -6.40
CPHD's Operating margin (%) is ranked lower than
1694914% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.50 vs. CPHD: -6.40 )
CPHD' s 10-Year Operating margin (%) Range
Min: -233.9   Max: 1.4
Current: -6.4
-233.9
1.4
Net-margin (%) -6.1
CPHD's Net-margin (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.60 vs. CPHD: -6.1 )
CPHD' s 10-Year Net-margin (%) Range
Min: -220.2   Max: 0.9
Current: -6.1
-220.2
0.9
ROE (%) -8.1
CPHD's ROE (%) is ranked lower than
1785713% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.30 vs. CPHD: -8.1 )
CPHD' s 10-Year ROE (%) Range
Min: -508.6   Max: 1.2
Current: -8.1
-508.6
1.2
ROA (%) -6
CPHD's ROA (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. CPHD: -6 )
CPHD' s 10-Year ROA (%) Range
Min: -162.1   Max: 0.9
Current: -6
-162.1
0.9
ROC (Joel Greenblatt) (%) -20.10
CPHD's ROC (Joel Greenblatt) (%) is ranked lower than
1694914% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.80 vs. CPHD: -20.10 )
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -829.3   Max: 5.5
Current: -20.1
-829.3
5.5
Revenue Growth (%) 14.5
CPHD's Revenue Growth (%) is ranked lower than
2173911% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. CPHD: 14.5 )
CPHD' s 10-Year Revenue Growth (%) Range
Min: 5.6   Max: 40
Current: 14.5
5.6
40
EBITDA Growth (%) -25.5
CPHD's EBITDA Growth (%) is ranked lower than
3448272% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.80 vs. CPHD: -25.5 )
CPHD' s 10-Year EBITDA Growth (%) Range
Min: -27.3   Max: 3.1
Current: -25.5
-27.3
3.1
EPS Growth (%) -6.3
CPHD's EPS Growth (%) is ranked lower than
5882347% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.10 vs. CPHD: -6.3 )
CPHD' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 4.4
Current: -6.3
-29.5
4.4
ยป CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CPHD Guru Trades in Q2 2012

Andreas Halvorsen 1,074,300 sh (New)
Columbia Wanger 5,893,500 sh (+16.81%)
Mario Gabelli 244,500 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,222,600 sh (-10.26%)
» More
Q3 2012

CPHD Guru Trades in Q3 2012

Andreas Halvorsen 2,591,610 sh (+141.24%)
Columbia Wanger 6,737,500 sh (+14.32%)
Mario Gabelli 244,500 sh (unchged)
PRIMECAP Management 2,205,600 sh (-0.76%)
» More
Q4 2012

CPHD Guru Trades in Q4 2012

Ron Baron 123,586 sh (New)
Steven Cohen 105,276 sh (New)
Columbia Wanger 6,737,500 sh (unchged)
Mario Gabelli 244,500 sh (unchged)
PRIMECAP Management 2,185,600 sh (-0.91%)
Andreas Halvorsen 2,505,210 sh (-3.33%)
» More
Q1 2013

CPHD Guru Trades in Q1 2013

Columbia Wanger 7,666,000 sh (+13.78%)
Ron Baron 123,729 sh (+0.12%)
Mario Gabelli 244,500 sh (unchged)
Andreas Halvorsen Sold Out
PRIMECAP Management 2,170,600 sh (-0.69%)
Steven Cohen 47,956 sh (-54.45%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2012-12-31 New Buy0.03%$28.72 - $35.71 $ 38.0918%123586
George Soros 2011-09-30 Sold Out 0.0029%$30.18 - $40.77 $ 38.099%0
George Soros 2011-06-30 Reduce -55.97%$28.54 - $34.07 $ 38.0922%5900
Mario Gabelli 2011-03-31 Reduce -52.3%0.05%$22.75 - $27.82 $ 38.0952%264000
George Soros 2011-03-31 New Buy$22.75 - $27.82 $ 38.0952%13400
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 10.40
CPHD's P/B is ranked lower than
1010100% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.64 vs. CPHD: 10.40 )
CPHD' s 10-Year P/B Range
Min: 1.17   Max: 21.88
Current: 10.4
1.17
21.88
P/S 7.37
CPHD's P/S is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.43 vs. CPHD: 7.37 )
CPHD' s 10-Year P/S Range
Min: 1.76   Max: 25.48
Current: 7.37
1.76
25.48
EV-to-EBIT 500
CPHD's EV-to-EBIT is ranked lower than
299% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. CPHD: 500 )
CPHD' s 10-Year EV-to-EBIT Range
Min: 285.6   Max: 744.4
Current: 500
285.6
744.4

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 211.6
CPHD's Price/Net Cash is ranked lower than
2127657% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. CPHD: 211.6 )
CPHD' s 10-Year Price/Net Cash Range
Min: 3.8   Max: 263.5
Current: 211.6
3.8
263.5
Price/Net Current Asset Value 37.3
CPHD's Price/Net Current Asset Value is ranked lower than
1149424% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.80 vs. CPHD: 37.3 )
CPHD' s 10-Year Price/Net Current Asset Value Range
Min: 19.6   Max: 51.7
Current: 37.3
19.6
51.7
Price/Tangible Book 13.3
CPHD's Price/Tangible Book is ranked lower than
1136363% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. CPHD: 13.3 )
CPHD' s 10-Year Price/Tangible Book Range
Min: 3.1   Max: 20.4
Current: 13.3
3.1
20.4
Price/DCF (Projected) 18.8
CPHD's Price/DCF (Projected) is ranked lower than
2702700% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. CPHD: 18.8 )
CPHD' s 10-Year Price/DCF (Projected) Range
Min: 24.2   Max: 58.3
Current: 18.8
24.2
58.3
Price/Median PS Value 1
CPHD's Price/Median PS Value is ranked lower than
1041666% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CPHD: 1 )
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 2.9
Current: 1
0.5
2.9
Earnings Yield (Greenblatt) 0.20
CPHD's Earnings Yield (Greenblatt) is ranked lower than
1388888% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. CPHD: 0.20 )
CPHD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.4
Current: 0.2
0.1
0.4
Forward Rate of Return (Yacktman) -0.15
CPHD's Forward Rate of Return (Yacktman) is ranked lower than
3030300% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.26 vs. CPHD: -0.15 )
CPHD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: -0.5
Current: -0.15
-0.9
-0.5

Business Description

Cepheid was incorporated in the State of California on March 4, 1996. Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its Non-Clinical legacy Biothreat, Industrial and Partner markets. The Company's systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company products portfolio consists of tests, reagents and systems for the Clinical and Non-Clinical markets. The Company's two principal systems are the GeneXpert and SmartCycler. The GeneXpert system, its main offering in the Clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The GeneXpert system is also its main system in the Biothreat market. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system, including the Infinity, represents a paradigm shift in molecular diagnostics in terms of ease-of-use and flexibility, producing accurate results in a timely manner with minimal risk of contamination. The Company's Xpert tests for use on the GeneXpert system are unique in that they typically require less than two minutes of hands-on time for unprecedented ease of use, rapid results, in most cases under an hour, and the ability to do testing in any workflow environment: full random access; on-demand; or traditional batch testing. The Company faces intense competition from a number of companies that offer products in its target markets, some of which have substantially greater financial resources and more established marketing, sales and service organizations than it do. In the Clinical market, the Company's products are regulated as medical device products by the FDA and comparable agencies in other countries.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:XEP.Germany
ยป More Articles for CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sells Highlight: PEET, TEN, VRSK, CPHD, GTAT, LINC Aug 15 2011 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial